Elanco Veterinary Drug Gains European Approval

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

The European Commission has granted marketing authorization to Indianapolis-based Elanco Animal Health and Kansas-based Aratana Therapeutics Inc. (Nasdaq: PETX) for a new veterinary medicine treatment. Elanco says the approval will allow the companies to market the drug Galliprant in the European Union.

Galliprant is prescribed to treat pain associated with mild-to-moderate osteoarthritis in dogs. Elanco has exclusive rights to develop, manufacture, market and commercialize the drug globally. The company co-promotes Galliprant with Aratana in the United States.

Elanco Animal Health is a division of Eli Lilly and Co. (NYSE: LLY) in Indianapolis.